StockNow
Log in
U.S. Markets

Moderna (MRNA) and Merck (MRK) vaccine succeeds in preventing Melanoma from returning, reports WSJ

StockNow breaking-news AI analysis

Moderna and Merck reported successful melanoma recurrence prevention with their mRNA vaccine, showing a 49% risk reduction. Phase 3 results are expected by late 2026, targeting a 2027 launch.

News detail

An experimental mRNA-based vaccine succeeded in preventing cancer from coming back or spreading in a study of high-risk melanoma patients, Moderna and its partner Merck said Wednesday, paving the way for a potentially new life-extending treatment for the thousands of people diagnosed with the deadly skin cancer each year.

2 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

Iranian Deputy Chairman of the Parliament's National Security Commission says "A 'new passage' in the Strait of Hormuz, other than the southern route, will soon be announced in the form of a joint statement with Oman"

Geopolitics

A source close to Iran's negotiating team rejected the White House's claim, saying there had been no direct Iran-US negotiations and that talks with Oman concerned sovereignty over the Strait of Hormuz, Fars News reports

U.S. Markets

Target (TGT) Q2 2026 (USD): Adj. EPS 4.11 (exp. 2.32), Revenue 26.5bln (exp. 26.12bln); lifts FY outlook to include tariff refunds, Adj. EPS 9.90-10.90 (prev. guided 7.50-8.50, exp. 8.52)

TGT